People with diabetic macular edema may get eye injections to help control their symptoms. These eye injections can improve vision and also stop the damage that causes vision to get worse. Most of ...

Eylea is a brand-name biologic prescription medication containing the active ingredient aflibercept. Generic versions of biologic drugs are called biosimilars. Due to the complex manufacturing process ...

How Does Eylea Work for Wet AMD? As you age, you may develop a condition that causes your vision to change. One of the most common eye conditions in older people is called age-related macular ...

Regeneron (REGN) Pharmaceuticals announced the primary endpoint was met in the Phase 3 QUASAR trial investigating EYLEA HD Injection 8 mg for the treatment of patients with macular edema following ...

Eylea and Eylea HD are prescription medications used to treat various eye conditions. The dosage and frequency of injections of these drugs vary based on the specific condition and the form of the ...

Regeneron Pharmaceuticals (NASDAQ:REGN) announced that the U.S. FDA has extended the target action dates for two regulatory submissions related to Eylea HD (aflibercept) injection 8 mg to the fourth ...

The US Food and Drug Administration (FDA) has accepted Regeneron Pharmaceuticals’ supplemental biologics licence application (sBLA) for Eylea HD (aflibercept) injection 8mg for priority review. The ...

Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA ® HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Injection 2 mg that were maintained with fewer ...

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.’s (NASDAQ: REGN) Eylea HD (aflibercept) Injection 8 mg for patients with macular edema following ...

TARRYTOWN, N.Y., April 29, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced the presentation of positive long-term results and subgroup analyses from the pivotal ...

TARRYTOWN, N.Y., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new analyses of EYLEA HD® (aflibercept) Injection 8 mg and EYLEA® (aflibercept) ...